FlandersBio on Twitter

Follow us on Twitter

News

Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Pulmocide Raises $30 Million in Series B Financing

20.03.2017

Pulmocide Ltd, the UK-based drug discovery company developing novel compounds designed for inhaled delivery to treat respiratory syncytial virus (RSV) and pulmonary aspergillosis, today announced the completion of a $30.4 million Series B financing round. The round was led by new investor SR One and included Longwood Fund plus existing investors SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation - JJDC, Inc. and Touchstone Innovations plc. read more

Kiadis Pharma appoints Jan Feijen as Chief Operations Officer

20.03.2017

Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces the appointment of Jan Feijen as Chief Operations Officer (COO) effective from April 1, 2017. read more

New plant research leads to the discovery of a gene that significantly increases seed yield in maize

17.03.2017

Researchers from VIB-UGent have discovered a gene that significantly increases plant growth and seed yield in maize. Research into crop yield is crucial because of the increasing incidence of extreme weather conditions affecting agriculture. The results from laboratory research were confirmed during two-year field trials conducted in Belgium and the United States showing that this gene can increase seed yield in maize hybrids by 10 to 15%. The results of the greenhouse and field trials are published in the scientific journal Nature Communications. read more

ThromboGenics NV : ThromboGenics Business Update - FY 2016

17.03.2017

- Innovative Diabetic Eye Disease Clinical and Pre-Clinical Portfolio Provides "Multiple Shots on Goal" - First Patients Enrolled in Phase II Clinical Study Evaluating THR-317 (anti-PlGF) for Diabetic Macular Edema (DME) - Cash Position - €80.1 Million at end of December 2016 read more

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

16.03.2017

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell-based therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has decided to reject a new reexamination request of Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a CAR. The patent remains valid and enforceable. read more

Kiadis Pharma to present information on the design of its Phase III trial with ATIR101™ and Phase I/II trial with ATIR201™ at 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation

16.03.2017

Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that abstracts providing information on the design of the Company’s recently initiated Phase III clinical trial with lead product ATIR101™ and Phase I/II clinical trial with ATIR201™, have been accepted for poster presentation on March 27 and 28, 2017 respectively at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France. read more

Bone Therapeutics Reports Full Year 2016 Results

16.03.2017

- Streamlined strategic priorities with primary focus on allogeneic pipeline - Strong progress in clinical development of allogeneic platform ALLOB® - Further demonstration of efficacy of autologous PREOB® in osteonecrosis - Cash at end of 2016: EUR 20.3 million - Management team strengthened with appointments of Thomas Lienard (CEO), Benoît Champluvier (CTMO) and Miguel Forte (CMO) read more

Promethera Biosciences to Present at Upcoming Industry Conferences

16.03.2017

CEO John Tchelingerian to Discuss Strategic Collobarations and Partnering Strategies in Cell Therapy at ARM’s Advanced Therapies Summit read more

Biocartis receives grant for development of a fully automated MSI test

15.03.2017

Test could be validated as prognostic test for colorectal cancer and predictive test for cancer immunotherapies read more

argenx announces Annual General Meeting of Shareholders 26 April 2017

15.03.2017

argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announces that an annual general meeting of shareholders will be held on Wednesday 26 April 2017. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print